SXTC vs CCRN

For growth investors, China SXT Pharmaceuticals, Inc.

(SXTC) is the stronger pick with -9. 7% revenue growth year-over-year, versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). Analysts rate Cross Country Healthcare, Inc. (CCRN) a "Hold" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Cross Country Healthcare, Inc.

(CCRN) delivered a total return of -23. 1%, compared to -100. 0% for China SXT Pharmaceuticals, Inc. (SXTC). Over 10 years, the gap is even starker: CCRN returned -9. 9% versus SXTC's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Cross Country Healthcare, Inc.

(CCRN) is the lower-risk stock at 0. 68β versus China SXT Pharmaceuticals, Inc. 's 1. 19β — meaning SXTC is approximately 76% more volatile than CCRN relative to the S&P 500. On balance sheet safety, Cross Country Healthcare, Inc. (CCRN) carries a lower debt/equity ratio of 1% versus 6% for China SXT Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), China SXT Pharmaceuticals, Inc.

(SXTC) is pulling ahead at -9. 7% versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). On earnings-per-share growth, the picture is similar: China SXT Pharmaceuticals, Inc. grew EPS -129. 1% year-over-year, compared to -565. 9% for Cross Country Healthcare, Inc.. Over a 3-year CAGR, SXTC leads at -12. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Cross Country Healthcare, Inc.

(CCRN) is the more profitable company, earning -9. 0% net margin versus -189. 8% for China SXT Pharmaceuticals, Inc. — meaning it keeps -9. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CCRN leads at -0. 3% versus -154. 0% for SXTC. At the gross margin level — before operating expenses — SXTC leads at 21. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Cross Country Healthcare, Inc.

(CCRN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 68)). Both have compounded well over 10 years (CCRN: -9. 9%, SXTC: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.